Targovax Revenue and Competitors
Estimated Revenue & Valuation
- Targovax's estimated annual revenue is currently $7M per year.
- Targovax's estimated revenue per employee is $155,000
Employee Data
- Targovax has 45 Employees.
- Targovax grew their employee count by 2% last year.
Targovax's People
Name | Title | Email/Phone |
---|---|---|
1 | Regulatory Affairs Manager | Reveal Email/Phone |
Targovax Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $16.4M | 106 | 29% | N/A | N/A |
#2 | $1.7M | 11 | -15% | N/A | N/A |
#3 | $3.7M | 24 | 4% | N/A | N/A |
#4 | $3.1M | 20 | -66% | N/A | N/A |
#5 | $5.4M | 35 | 9% | N/A | N/A |
#6 | $7M | 45 | 2% | N/A | N/A |
#7 | $9.8M | 63 | -14% | N/A | N/A |
#8 | $8.5M | 55 | 28% | N/A | N/A |
What Is Targovax?
Activating the Patient's Immune System to Fight Cancer Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine. Targovax's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It is used as a therapeutic cancer vaccine, and has a proven ability to activate the immune system and generate tumor-specific immune responses. In phase I trials, ONCOS-102 has demonstrated innate and adaptive immune activation, both locally and systemically, which has been associated with clinical benefit. ONCOS-102's lead indication is mesothelioma, where the virus is currently being tested in a randomized phase Ib/II trial. Another trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients within the next 6-12 months. Targovax is also developing a neo-antigen cancer vaccine targeting tumors that express mutated forms of RAS. The TG vaccine program has shown a signal of efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently being combined with Keytruda® (pembrolizumab) in a phase Ib trial in colorectal cancer. Both the ONCOS and TG programs are protected by a portfolio of IP and know-how, and have the potential to generate multiple product candidates.
keywords:N/AN/A
Total Funding
45
Number of Employees
$7M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Targovax News
Reference is made to the annual general meeting of Targovax ASA (the "Company") on 20 April 2022 (the "AGM") where election of members to...
Oslo, Norway , 21 April 2022 - Targovax ASA (OSE: TRVX) announces that the. General Meeting has elected Dr Raphael Clynes and Mr Thomas...
2022 Targovax ASA AGM minutes.pdf. ***. For further information, please contact: Erik Digman Wiklund , CEO Phone: +47 413 33 536
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $9.1M | 45 | 36% | N/A |
#2 | $5.2M | 45 | -25% | $6M |
#3 | $5.2M | 45 | -17% | N/A |
#4 | $5.2M | 45 | 181% | N/A |
#5 | $5.2M | 46 | 0% | N/A |